2016
αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor
Lu H, Wang T, Li J, Fedele C, Liu Q, Zhang J, Jiang Z, Jain D, Iozzo RV, Violette SM, Weinreb PH, Davis RJ, Gioeli D, FitzGerald TJ, Altieri DC, Languino LR. αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor. Cancer Research 2016, 76: 5163-5174. PMID: 27450452, PMCID: PMC5012867, DOI: 10.1158/0008-5472.can-16-0543.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigens, NeoplasmCell Line, TumorDisease Models, AnimalFlow CytometryFluorescent Antibody TechniqueGene Knockdown TechniquesHumansImmunohistochemistryIntegrinsMaleMiceMice, KnockoutMitogen-Activated Protein Kinase 8Prostatic Neoplasms, Castration-ResistantReceptors, AndrogenSignal TransductionConceptsΑvβ6 expressionAndrogen receptorProstate cancerΑvβ6 integrinCastrate-resistant prostate cancerProstate cancer mouse modelAbsence of androgenFurther clinical developmentProstate cancer therapyCancer mouse modelNormal prostatic epitheliumProstate cancer progressionΑv-containing integrinsMajor therapeutic targetUpregulation of survivinActivation of JNK1Androgen ablationDownstream kinase activationMechanisms of resistanceProstatic adenocarcinomaInvolvement of p38Preclinical resultsMouse modelProstatic epitheliumClinical development
2010
Expanding spectrum of the association between Type 1 Gaucher disease and cancers: A series of patients with up to 3 sequential cancers of multiple types—Correlation with genotype and phenotype
Lo SM, Stein P, Mullaly S, Bar M, Jain D, Pastores GM, Mistry PK. Expanding spectrum of the association between Type 1 Gaucher disease and cancers: A series of patients with up to 3 sequential cancers of multiple types—Correlation with genotype and phenotype. American Journal Of Hematology 2010, 85: 340-345. PMID: 20425796, PMCID: PMC2875938, DOI: 10.1002/ajh.21684.Peer-Reviewed Original ResearchConceptsType 1 Gaucher's diseaseGaucher diseaseMultiple myelomaMultiple malignanciesMultiple cancersEnzyme replacement therapy statusDiagnosis of GD1Initiation of ERTRate of splenectomySeries of patientsSystemic macrophage activationTypes of malignanciesLymphoma/leukemiaAccumulation of glucosylceramideAsplenic patientsGBA1 genotypeGD1 patientsSequential cancersFirst cancerSplenectomy statusTherapy statusNonhematologic malignanciesHematologic malignanciesIntact spleenProstate cancer
2009
Molecular markers and death from prostate cancer.
Concato J, Jain D, Uchio E, Risch H, Li WW, Wells CK. Molecular markers and death from prostate cancer. Annals Of Internal Medicine 2009, 150: 595-603. PMID: 19414838, DOI: 10.7326/0003-4819-150-9-200905050-00005.Peer-Reviewed Original ResearchConceptsProstate-specific antigen levelProstate cancerLong-term riskAntigen levelsMicrovessel densityMedian prostate-specific antigen levelIncreased long-term riskVeterans Affairs Healthcare SystemIncident prostate cancerObservational cohort studyProportional hazards analysisTime of diagnosisHigher microvessel densityVeterans Health AdministrationBcl-2Years of ageProstate cancer biopsiesClinical care recordsClinical characteristicsCohort studyPatient ageMedian ageComorbid conditionsHistologic gradeResidual confounding
2007
Molecular markers and mortality in prostate cancer
Concato J, Jain D, Li WW, Risch HA, Uchio EM, Wells CK. Molecular markers and mortality in prostate cancer. BJU International 2007, 100: 1259-1263. PMID: 17850375, DOI: 10.1111/j.1464-410x.2007.07136.x.Peer-Reviewed Original ResearchConceptsProstate cancerPrognostic factorsMedical recordsMicrovessel densityMedian prostate-specific antigen levelProstate-specific antigen levelVeterans Affairs Medical CenterIncident prostate cancerLong-term mortalityCommunity-based populationPotential prognostic factorsTraditional prognostic factorsHigher microvessel densityTraditional clinical factorsAvailable medical recordsIndependent effectsBcl-2 stainingClinical factorsIndependent predictorsMedian ageOverall mortalityAdjusted analysisAntigen levelsMedical CenterAmbulatory care